Viridian Therapeutics (VRDN) Analyst & Key Data

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts24

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$21.24

Median Target+83.43%

$38.96

Potential upside vs current price

DCF Value-131.09%

-$6.60

Potential downside vs current price

Current Stock Price

$21.24

Median Target+83.43%

$38.96

Potential upside vs current price

DCF Value-131.09%

-$6.60

Potential downside vs current price

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts24

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$21.24

Median Target+83.43%

$38.96

Potential upside vs current price

DCF Value-131.09%

-$6.60

Potential downside vs current price

Current Stock Price

$21.24

Median Target+83.43%

$38.96

Potential upside vs current price

DCF Value-131.09%

-$6.60

Potential downside vs current price

Viridian Therapeutics, Inc.